scholarly journals Outcome of SIOP patients with low- or intermediate-risk Wilms tumour relapsing after initial vincristine and actinomycin-D therapy only − the SIOP 93–01 and 2001 protocols

2022 ◽  
Vol 163 ◽  
pp. 88-97
Author(s):  
Alissa Groenendijk ◽  
Harm van Tinteren ◽  
Yilin Jiang ◽  
Ronald R. de Krijger ◽  
Gordan M. Vujanic ◽  
...  
Keyword(s):  
Actinomycin D ◽  
Intermediate Risk ◽  
Wilms Tumour

scholarly journals Spontaneous rupture of adult Wilms’ tumor: A case report and review of the literature

2015 ◽  
Vol 9 (7-8) ◽  
pp. 531 ◽  
Author(s):  
Jian-lin Huang ◽  
Yong Liao ◽  
Ming-xing Qiu
Keyword(s):  
Radical Nephrectomy ◽  
Spontaneous Rupture ◽  
Preoperative Diagnosis ◽  
Actinomycin D ◽  
Wilms Tumor ◽  
Review Of The Literature ◽  
Wilms Tumour ◽  
Retroperitoneal Hemorrhage ◽  
Comprehensive Therapy

Wilms’ tumour is rare in adults, and spontaneous rupture with retroperitoneal hemorrhage as the presenting sign of renal tumour is also uncommon. We present a case of a 20-year-old woman with spontaneous rupture of Wilms’ tumour by describing the course of diagnosis and treatment. The patient underwent an open left radical nephrectomy, and was treated with 18 weeks of adjuvant chemotherapy with vincristine and actinomycin D. The follow-up of 12 months demonstrated no recurrence. We also reviewed the limited number of related reports. These suggest that the preoperative diagnosis of adult Wilms’ tumour is very difficult, and radical nephrectomy and postoperative comprehensive therapy are equally important in the treatment of these patients. Factors of prognosis for adults with Wilms’ tumour include tumour stage, histopathology, and time and type of therapy.

scholarly journals Is Not It the Time to Change the Treatment of Intermediate-Risk Patients Suffering From Gestational Trophoblastic Neoplasia?

2019 ◽  
Vol 8 (2) ◽  
pp. 153-157
Author(s):  
Setareh Akhavan ◽  
Mitra Modarres Gilani ◽  
Azamosadat Mousavi ◽  
Sahrzad Sheikh Hasani ◽  
Fahimeh Nokhostin
Keyword(s):  
Tumor Invasion ◽  
Doppler Ultrasonography ◽  
Actinomycin D ◽  
Close Association ◽  
Single Agent ◽  
World Health ◽  
Intermediate Risk ◽  
Gestational Trophoblastic Neoplasia ◽  
Risk Scoring ◽  
Invasion Pattern

Objectives: The present study attempted to provide a clear view of gestational trophoblastic neoplasia (GTN) with the focus on resistance to treatment approaches in Iran. Materials and Methods: This retrospective cohort study reviewed the medical records of 272 patients with the definitive diagnosis of GTN referring to Imam Khomeini hospital in Tehran during 2007-2017. Results: The mean age of participants was 29.19 ± 7.46 years. The abnormal uterine bleeding (AUB) was the most common clinical manifestation in 64.3% of patients. Regarding the risk scoring condition according to the World Health Organization criteria, 77.6%, 9.1%, and 13.3% were categorized as low-, intermediate-, and high-risk cases. Single therapy with methotrexate was used in 22.8% of patients and actinomycin-D was planned for 42.3% whereas 11.0% and 1.5% were considered for treatment with the EMA-CO (Etoposide, methotrexate, actinomycin D, cyclophosphamide, vincristine) and EMA-EP (Etoposide methotrexate and actinomycin-D/ etoposide and cisplatin) regimens, respectively. Good response to methotrexate was 66.7% but it was 83.6% in the ACT group (P = 0.001). The resistance to single-agent chemotherapy in low- and intermediate-risk groups was 16% and 92%, respectively. In addition, 20.2% of patients in stage one had tumor invasion pattern in the uterus in pretreatment Doppler ultrasonography, but 52% and 30% had resistance to chemotherapy treatment in invasive and noninvasive groups, respectively (P = 0.008). Conclusions: In general, due to the high resistance of the intermediate-risk subgroup to a single therapy, a combination therapy may be more useful to treat this disorder. The close association between tumor invasion pattern in the uterus in Doppler ultrasonography and drug resistance can be considered as a new criterion for tumor risk scoring.

Doxorubicin in stage II–III, intermediate-risk Wilms' tumour

The Lancet ◽  
2015 ◽  
Vol 386 (9999) ◽  
pp. 1118-1119 ◽  
Author(s):  
Daniel M Green
Keyword(s):  
Stage Ii ◽  
Intermediate Risk ◽  
Wilms Tumour

scholarly journals Omission of doxorubicin from the treatment of stage II–III, intermediate-risk Wilms' tumour (SIOP WT 2001): an open-label, non-inferiority, randomised controlled trial

The Lancet ◽  
2015 ◽  
Vol 386 (9999) ◽  
pp. 1156-1164 ◽  
Author(s):  
Kathy Pritchard-Jones ◽  
Christophe Bergeron ◽  
Beatriz de Camargo ◽  
Marry M van den Heuvel-Eibrink ◽  
Tomas Acha ◽  
...  
Keyword(s):  
Randomised Controlled Trial ◽  
Controlled Trial ◽  
Stage Ii ◽  
Intermediate Risk ◽  
Wilms Tumour ◽  
Open Label ◽  
Randomised Controlled

scholarly journals Evaluation of boost irradiation in patients with intermediate-risk stage III Wilms tumour with positive lymph nodes only: Results from the SIOP-WT-2001 Registry

2018 ◽  
Vol 65 (8) ◽  
pp. e27085 ◽  
Author(s):  
Raquel Dávila Fajardo ◽  
Eva Oldenburger ◽  
Christian Rübe ◽  
Marta López-Yurda ◽  
Kathy Pritchard-Jones ◽  
...  
Keyword(s):  
Lymph Nodes ◽  
Stage Iii ◽  
Intermediate Risk ◽  
Wilms Tumour ◽  
Boost Irradiation ◽  
Positive Lymph Nodes
Sign in / Sign up

Export Citation Format

Share Document